These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 10204653

  • 1. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
    Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF.
    Int Angiol; 1998 Dec; 17(4):225-33. PubMed ID: 10204653
    [Abstract] [Full Text] [Related]

  • 2. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
    Am J Ther; 2007 Dec; 14(2):213-20. PubMed ID: 17414592
    [Abstract] [Full Text] [Related]

  • 3. [Effectiveness of ciprofibrate. Open study in a Portuguese population].
    Silva JM, Branco MC, Pereira M, Figueiredo H, Jesus LC, de Moura JP, Ferreira MR, Serra e Silva P.
    Rev Port Cardiol; 1995 Apr; 14(4):313-22, 284. PubMed ID: 7612280
    [Abstract] [Full Text] [Related]

  • 4. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA, Koro CE, Chan W, Bowlin SJ, Sprecher DL.
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [Abstract] [Full Text] [Related]

  • 5. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
    Dobiásová M, Frohlich J.
    Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517
    [Abstract] [Full Text] [Related]

  • 6. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
    Kovács I, Tarján J, Császár A.
    Orv Hetil; 2001 Apr 15; 142(15):775-9. PubMed ID: 11367862
    [Abstract] [Full Text] [Related]

  • 7. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
    Espinosa RA, Rodríguez-Roa E, Nagy E, Mijares ME, Rodríguez-Larralde A, Gil A, Lundberg U, Carvajal Z, Castillo L, Arocha-Piñango CL.
    Invest Clin; 2006 Mar 15; 47(1):35-48. PubMed ID: 16562643
    [Abstract] [Full Text] [Related]

  • 8. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M.
    J Cardiovasc Pharmacol Ther; 2002 Oct 15; 7(4):219-26. PubMed ID: 12490967
    [Abstract] [Full Text] [Related]

  • 9. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 15; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 10. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS.
    Clin Ther; 2007 Jul 15; 29(7):1403-14. PubMed ID: 17825691
    [Abstract] [Full Text] [Related]

  • 11. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.
    Clin Ther; 2007 Aug 15; 29(8):1671-81. PubMed ID: 17919548
    [Abstract] [Full Text] [Related]

  • 12. Factors associated with changes in serum total cholesterol levels over 7 years in middle-aged New Zealand men and women: a prospective study.
    Metcalf PA, Scragg RK, Swinburn BA, Shaw LM.
    Nutr Metab Cardiovasc Dis; 2001 Oct 15; 11(5):298-305. PubMed ID: 11887426
    [Abstract] [Full Text] [Related]

  • 13. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
    Dupuy AM, Carrière I, Scali J, Cristol JP, Ritchie K, Dartigues JF, Gambert P, Ancelin ML.
    Climacteric; 2008 Feb 15; 11(1):74-83. PubMed ID: 18202967
    [Abstract] [Full Text] [Related]

  • 14. Does obesity influence ciprofibrate activity?
    Silva JM, Serra e Silva P.
    Rev Port Cardiol; 1998 Apr 15; 17(4):329-34. PubMed ID: 9632956
    [Abstract] [Full Text] [Related]

  • 15. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
    Imperato F, Marziani R, Perniola G, Ebano V, Fruscella M, Mossa B.
    Minerva Ginecol; 2003 Feb 15; 55(1):87-93. PubMed ID: 12598849
    [Abstract] [Full Text] [Related]

  • 16. Treatment of high-risk older persons with lipid-lowering drug therapy.
    Aronow WS.
    Am J Ther; 2008 Feb 15; 15(2):102-7. PubMed ID: 18356628
    [Abstract] [Full Text] [Related]

  • 17. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW.
    Curr Med Res Opin; 2001 Feb 15; 17(1):60-73. PubMed ID: 11464448
    [Abstract] [Full Text] [Related]

  • 18. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.
    Metabolism; 2001 Jun 15; 50(6):729-33. PubMed ID: 11398153
    [Abstract] [Full Text] [Related]

  • 19. Effect of red wine and red grape extract on blood lipids, haemostatic factors, and other risk factors for cardiovascular disease.
    Hansen AS, Marckmann P, Dragsted LO, Finné Nielsen IL, Nielsen SE, Grønbaek M.
    Eur J Clin Nutr; 2005 Mar 15; 59(3):449-55. PubMed ID: 15674304
    [Abstract] [Full Text] [Related]

  • 20. Observed changes in the lipid profile and calculated coronary risk in patients given dietary advice in primary care.
    Price D, Ramachandran S, Knight T, Jones PW, Neary RH.
    Br J Gen Pract; 2000 Sep 15; 50(458):712-5. PubMed ID: 11050787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.